Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled salbutamol for transient tachypnea of the newborn
IRCT20250814066854N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of salbutamol in transient tachypnea of the newborn (TTN) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Duration of NICU hospitalization, Time to achieve oral feeding and 2 more. Started Oct 2025; status: completed.
02
Drugs
salbutamol
03
Conditions
transient tachypnea of the newborn (TTN)
Beyond the preview
Go deeper on IRCT20250814066854N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250814066854N1.